Arcalyst (rilonacept) — Medica
Neonatal onset multisystem inflammatory disease (NOMID) formerly known as chronic infantile neurological cutaneous and articular syndrome (CINCA)
Initial criteria
- Patient is age ≥ 12 years
- Medication is prescribed by or in consultation with a rheumatologist, geneticist, allergist/immunologist, or dermatologist
Reauthorization criteria
- Patient has been established on this medication for at least 6 months
- When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR compared with baseline, patient experienced an improvement in at least one symptom
Approval duration
initial: 6 months; renewal: 1 year